文献速递肺外科

微创肺段切除术与肺叶切除术治疗外周IA1-2期非小细胞肺癌:英国中心病例匹配队列研究

Minimally invasive segmentectomy and lobectomy for peripheral stage IA1-2 non-small-cell lung cancer: a case-matched cohort study from a UK Centre.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

该单中心队列研究纳入2017年1月至2022年8月接受微创肺段或肺叶切除的外周临床IA期非小细胞肺癌连续患者,倾向性评分匹配出118对。中位随访30个月,两组90天死亡率、3年总生存率和无事件生存率均无显著差异,肺段切除组淋巴结升期率更低。

要点

  • 外周IA期非小细胞肺癌微创肺段切除与肺叶切除的3年总生存率和无事件生存率无显著差异。
  • 肺段切除组淋巴结升期率3.4%低于肺叶切除组14%,差异有统计学意义。
  • 两组局部区域复发率、切缘受累情况及90天死亡率均相似。

核心结论

  • 该观察性系列证实,对于外周IA期非小细胞肺癌,肺段切除术相较于肺叶切除术非劣效。

研究设计与样本

  • 单中心队列研究,纳入2017年1月至2022年8月连续接受微创肺段或肺叶切除的外周(肺外三分之一)临床IA期非小细胞肺癌患者。
  • 采用倾向性评分病例匹配分析生成118对分别接受肺段切除或肺叶切除的匹配患者。

主要发现

  • 中位随访30个月(95%置信限4-64)。
  • 术后中位住院时间两组均为4天。
  • 90天死亡率:肺段切除组2.5% vs 肺叶切除组1.7%,P=1。
  • 3年总生存率:肺段切除组87%(76-93)vs 肺叶切除组81%(72-88),P=0.73;3年无事件生存率:肺段切除组82%(72-90)vs 肺叶切除组78%(68-84),P=0.52。
  • 局部区域复发率:肺段切除组4.2%(5/118)vs 肺叶切除组9.3%(11/118),P=0.19;淋巴结升期率:肺段切除组3.4%(4/118)vs 肺叶切除组14%(17/118),P=0.005。

关键数值与推荐

  • 切缘受累(pR1或pR不确定)发生率:肺段切除组7.6%(9/118)vs 肺叶切除组9.3%(11/118),P=0.81。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study is to compare in a real-world series the short- and long-term results of segmentectomy and lobectomy for peripheral clinical stage IA non-small-cell lung cancer (NSCLC). METHODS: Single-centre cohort study including a series of consecutive patients undergoing minimally invasive segmentectomy or lobectomy for peripheral (outer third of the lung) clinical stage IA NSCLC (January 2017-August 2022). Propensity score case matching analysis generated 2 matched groups of patients undergoing segmentectomy or lobectomy. Short-term (morbidity and mortality) and long-term [overall survival and event-free survival (EFS)] outcomes were compared between the 2 matched groups. EFS was calculated by including death resulting from any cause and any recurrence as events. RESULTS: Propensity score generated 118 pairs of patients undergoing minimally invasive segmentectomy or lobectomy. The median follow-up was 30 months (95% confidence limits (CL) 4-64). The median postoperative length of stay was 4 days in both groups. Ninety-day mortality was similar (segmentectomy 2.5% versus lobectomy 1.7%, P = 1). Three-year overall survival [segmentectomy 87% (76-93) versus lobectomy 81% (72-88), P = 0.73] and EFS [segmentectomy 82% (72-90) versus lobectomy 78% (68-84), P = 0.52] did not differ between the groups. Loco-regional recurrence rate [segmentectomy 4.2% (5/118) versus lobectomy 9.3% (11/118), P = 0.19] was similar despite a lower nodal upstaging [segmentectomy 3.4% (4/118) versus lobectomy 14% (17/118), P = 0.005]. The occurrence of compromised resection margins (pR1 or pR uncertain) was similar between the groups [segmentectomy 7.6% (9/118) versus lobectomy 9.3% (11/118), P = 0.81]. CONCLUSIONS: This observational series confirms the non-inferiority of segmentectomy compared to lobectomy in treating peripherally located stage IA NSCLC.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Brunelli A, Rushwan A, Stefanou D, et al. Minimally invasive segmentectomy and lobectomy for peripheral stage IA1-2 non-small-cell lung cancer: a case-matched cohort study from a UK Centre. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 38092061. doi:10.1093/icvts/ivad204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。